SCHEMBL15840654

SCHEMBL15840654

CCCCc1ccc(NC(=S)Nc2ccc(S(=O)(=O)Nc3ccc(Cl)cc3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIA P62937 2/20 0.63
FFAR1 O14842 1/20 0.62
FFAR4 Q5NUL3 1/20 0.62
IDH1 O75874 1/20 0.59
GHSR Q92847 3/20 0.58
ALDH1A1 P00352 3/20 0.58
PPARG P37231 3/20 0.58
POLB P06746 1/20 0.57
LMNA P02545 2/20 0.57
MAPK1 P28482 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MEN1 O00255 1/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 1/20 0.57
BACE1 P56817 1/20 0.56
MAPT P10636 1/20 0.55
XBP1 P17861 1/20 0.55
CES1 P23141 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27812546 0.90 FFAR1 (0.74) FFAR1FFAR4IDH1GHSRALDH1A1
SCHEMBL15840672 0.89 ALDH1A1 (0.63) FFAR1FFAR4GHSRALDH1A1LMNA
SCHEMBL24324833 0.82 CES1 (0.69) FFAR1FFAR4ALDH1A1HTTBACE1
SCHEMBL15840818 0.81 PPIA (0.74) PPIAALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL31681351 0.80 FFAR4 (0.81) FFAR1FFAR4GHSRPOLBLMNA
SCHEMBL7173225 0.79 FFAR1 (0.74) FFAR1FFAR4GHSRPOLBLMNA
SCHEMBL25132396 0.79 ALDH1A1 (0.74) PPIAALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL15840711 0.79 ALDH1A1 (0.74) PPIAALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL7151939 0.79 FFAR1 (0.78) FFAR1FFAR4GHSRPOLBCA2
SCHEMBL15840715 0.79 PPIA (0.70) PPIAIDH1GHSRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 PPIA 1884/4885FFAR1 2431/4885FFAR4 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.